A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
SWOG Cancer Research Network
Canadian Cancer Trials Group
University of California, San Francisco
Stanford University
National Institutes of Health Clinical Center (CC)